Restore Vision Announces First Patient Dosed in Phase I/II Clinical Trial of RV-001 for Gene-Agnostic Retinitis Pigmentosa
The first optogenetic "Chimeric Rhodopsin" gene therapy tested in humans. RV-001 starting dose was generally well tolerated in this open-label trial. RV-001 a gene-agnostic approach for RP patients. TOKYO, Feb. 13, 2025 /PRNewswire/ -- Restore...
Neurizon Files IND Application to Support HEALEY ALS Platform Trial
Highlights: IND application submission to the U.S. Food and Drug Administration (FDA) is a pivotal step in initiating a Phase 2/3 clinical study for NUZ-001 The IND is a comprehensive dossier of information, including animal and human studies,...
J INTS BIO and MD Anderson Collaborate on the Development of Brain Tumor Treatment 'JIN-001' - Enhancing Radiation and Chemotherapy Efficacy
SEOUL, South Korea, Nov. 25, 2024 /PRNewswire/ -- J INTS BIO announced research findings on its innovative brain tumor treatment, 'JIN-001,' developed in collaboration with MD Anderson Cancer Center, at the 2024 Society of Neuro-Oncology (SNO)...
